Gelonghui, March 22, 丨 Kunming Pharmaceutical Group (600422.SH) announced its 2022 annual report. It achieved operating income of 8.282 billion yuan, an increase of 0.35% over the previous year; net profit attributable to shareholders of listed companies was 383 million yuan, a decrease of 24.52% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 251 million yuan, a decrease of 10.17% over the previous year; and basic earnings per share of 0.51 yuan. It is proposed to distribute a cash dividend of 1.60 yuan (tax included) for every 10 shares to all shareholders.